CMS seeks to reverse prior stacking guidance and proposes novel transparency requirements for High-Cost Drugs

On May 23, 2023, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that addresses a variety of important drug pricing…

Related Keywords

District Of Columbia ,United States ,American , ,Medicaid Services Investment ,Human Services ,Medicaid Drug Rebate Program ,Us Centers For Medicare Medicaid Services ,B Drug Pricing Program ,Medicaid Program ,Department Of Health ,Allergan Sales ,Us District Court ,National Drug Codes Ndcs ,B Program ,Medicaid Services ,Best Price ,Cumulative Discounts ,Covered Outpatient Drug Final Rule ,Drug Codes ,Accountability Act ,Federal Financial Participation ,Average Manufacturer Price ,National Drug Rebate Agreement ,Drug Rebate ,Drug Pricing ,Manufacturer Audit ,Covered Outpatient ,Internal Investigation ,Connection With ,Cost Transparency ,Medicaid Managed Care ,All Covered Outpatient Physician Administered ,Deficit Reduction Act ,Accumulator Adjustment Rule ,Accumulator Adjustment ,Medicaid Rebate ,American Rescue Plan Act ,Law ,Lawyers ,Legal ,Aw Firms ,Aw Updates ,Egal Updates ,Egal Developments ,Aw Developments ,Egal Newsletters ,Egal Current Awareness ,Deals ,Egal Advisers ,Egal Advisors ,Egal Directory ,Sa ,Ealthcare Amp Life Sciences ,